Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2023 · 10-Q
Revenue$9.20M$9.20M+12.4% vs Q3 2022 Net Income-$186.00K-$186.00KN/M vs Q3 2022 EPS Diluted-$0.04-$0.04N/M vs Q3 2022 Gross Profit$5,382,000+13.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,105,000N/M Free Cash Flowderived$953,000N/M Margins · derivedGross margin58.5%+0.7 pt vs Q3 2022
Operating margin4.5%+14.0 pt vs Q3 2022
Net margin-2.0%+171.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end